F4 FundFund
TeamPortfolioRaiseEssays
Sign in
Investment ThesisInvestment TeamF4 Research BriefSelected PortfolioRecent UpdatesFrequent co-investorsSimilar Firms
Hot Fund
#20 · Biotech 50 · 2026

Alpha Wave Global

alphawaveglobal.com · New York, NY

“Backs power law companies defining the AI era, plus category leaders across biotech, fintech, mobility, and consumer, deployed via private equity, private credit, public markets, and insurance/retirement solutions.”

$29B
AUM
01Investment Thesis

Backs power law companies defining the AI era, plus category leaders across biotech, fintech, mobility, and consumer, deployed via private equity, private credit, public markets, and insurance/retirement solutions.

Exclusion Criteria

Not a seed or early-stage investor; focuses on growth, late-stage, and pre-IPO scale businesses.

02Investment Team
RG
Rick Gerson
Co-Founder, Chairman & Chief Executive Officer
ND
Navroz D. Udwadia
Co-Founder and Partner
RK
Ryan Khoury
Co-Founder and Partner
RT
Ravi Thakran
Partner
FS
Francis Suarez
President
MC
Matthew Corey
Co-Chief Operating Officer and Chief Financial Officer
CW
Cathy Weist
Co-Chief Operating Officer and General Counsel
03F4 Research Brief

Alpha Wave Global Research

Investment Thesis

Alpha Wave Global (originally founded as Falcon Edge Capital in 2012) is a global alternative asset manager, not a traditional early-stage VC. The firm's public positioning centers on backing "power law companies that are defining the AI era" — outsized, category-defining businesses across AI, space, fintech, consumer, and hospitality. Alpha Wave operates across four verticals: private equity, private credit, public markets, and insurance/retirement solutions, giving it a much broader mandate than a typical venture fund. It ranked #20 in Biotech in the Strebulaev-Jackson 2026 VC ranking, reflecting a substantial and increasingly visible life sciences program alongside its AI and fintech bets.

Sector Focus

The portfolio spans an unusually wide range of sectors: AI infrastructure and applications (Anthropic, OpenAI, Cerebras, Cognition), aerospace (SpaceX), fintech and payments (Ramp, Klarna, Monzo, Revolut, CRED), biotech and life sciences (AbCellera, Amylyx, Apnimed, ATAI, HistoSonics, Transcend Therapeutics), mobility (Uber, Lyft, Ola Electric, DiDi), e-commerce and marketplaces (Alibaba, Swiggy, Delivery Hero), crypto/web3 (Animoca Brands, Polygon, Yuga Labs), consumer products (AG1, Lenskart), food and beverage (Chaayos, Haldirams, Kopi Kenangan), logistics (Delhivery, Locus), edtech (Cuemath, Classplus), and luxury hospitality (Aman). Biotech and life sciences is a clear and growing concentration within the portfolio, consistent with its ranked position.

Stage Focus

Alpha Wave invests primarily at growth, late-stage, and pre-IPO — participating in large financings (Series D through pre-IPO rounds, and secondaries) rather than seed or early Series A. Several portfolio companies (Cerebras, Apnimed) have IPO'd with Alpha Wave as a pre-IPO backer.

Check Size

No specific check-size range is published. Given the fund's ~$29B AUM and participation in rounds like Ramp's Series F ($44B valuation) and Anthropic's Series G ($30B raise), typical checks are likely in the tens to hundreds of millions of dollars. This should be treated as a low-confidence estimate.

Lead Tendency

Unclear from public sources whether Alpha Wave typically leads. It participates alongside large syndicates in mega-rounds (Anthropic, Ramp, Cognition) and has also anchored dedicated growth rounds (AdvanCell Series D). Classified as unknown pending deal-level confirmation.

Recent Activity

Alpha Wave has been highly active through 2026: Apnimed's upsized US IPO (July 2026), AdvanCell's $315M Series D (July 2026), the completed Transcend Therapeutics acquisition by Otsuka Pharmaceutical (June 2026), Ramp's Series F at a $44B valuation (June 2026), Cognition's $1B+ raise at a $26B valuation (May 2026), Cerebras's $5.6B IPO (May 2026), and Anthropic's $30B Series G at a $380B post-money valuation (February 2026). This cadence indicates an actively deploying fund with strong exposure to both AI infrastructure and biotech exits.

Portfolio Highlights

Portfolio spans 150+ companies. Marquee names include Anthropic, OpenAI, SpaceX, Cerebras, Ramp, Cognition, Klarna, Monzo, Revolut, Uber, Alibaba, TikTok, and Polygon. On the biotech side: AbCellera, Amylyx, Apnimed, ATAI, HistoSonics, KSQ, Life Biosciences, and Transcend Therapeutics (acquired by Otsuka in 2026). Notable exits/IPOs include Cerebras (IPO), Apnimed (IPO), and Transcend Therapeutics (acquired by Otsuka Pharmaceutical).

Team

  • Rick Gerson — Co-Founder, Chairman & Chief Executive Officer
  • Navroz D. Udwadia — Co-Founder and Partner
  • Ryan Khoury — Co-Founder and Partner
  • Ravi Thakran — Partner; former Group Chairman, LVMH Moët Hennessy Louis Vuitton Group Asia
  • Francis Suarez — President
  • Matthew Corey — Co-Chief Operating Officer and Chief Financial Officer
  • Cathy Weist — Co-Chief Operating Officer and General Counsel

No LinkedIn URLs or emails were published on the leadership page.

Decision Process

Not publicly documented. Given the firm's scale (multi-vertical alternative asset manager with 11 offices) and the seniority of its named leadership, deals are almost certainly run through an investment-committee process rather than a solo GP.

Founder Preferences

No explicit founder-preference language published. Portfolio skews toward category leaders and late-stage businesses with proven scale (SpaceX, Anthropic, Uber, Alibaba) rather than unproven early teams, suggesting a preference for founders who have already de-risked product-market fit.

Geographic Focus

Global. Alpha Wave maintains 11 offices across 8 countries: Miami, New York, London, Monaco, Madrid, Abu Dhabi, Tel Aviv, Bangalore, Mumbai, New Delhi, and Sydney. Headquartered in New York. Portfolio reflects strong US and India exposure, with meaningful presence in the Middle East, Europe, and China.

04Selected Portfolio
Aerospace & Defense
Spacex
Biotech & Life Sciences
AbCellera·Apnimed·Transcend Therapeutics·Amylyx·HistoSonics·Life Biosciences·AdvanCell
Consumer Apps & Social
TikTok
E-commerce & Marketplaces
Klarna·Alibaba·Swiggy·Delivery Hero·Getir·Lenskart·Moglix
EdTech
Cuemath
Enterprise Software
Anthropic·OpenAI·Cerebras·Cognition·ATAI
Fintech & Payments
Monzo·Revolut·Pine Labs·CRED
Food & Beverage
AG1
Insurance
Policy Bazaar
Logistics & Supply Chain
Uber·Delhivery
Mobility & Transportation
lyft.com·Ola Electric
Travel & Hospitality
Aman
Other
Ramp·Polygon·Animocabrands
Open the full portfolio→
05Recent Updates

Fresh signals from public announcements, essays, and portfolio activity.

See full activity (7) →
Portfolio company Apnimed's shares jumped after an upsized US IPO.
MILESTONE·finance.yahoo.com
JUL 31, 2026
AdvanCell closed a $315M oversubscribed Series D to advance targeted alpha therapies.
INVESTMENT·businesswire.com
JUL 15, 2026
Portfolio company Ramp raised a Series F at a $44B valuation.
MILESTONE·prnewswire.com
JUN 4, 2026
Portfolio company Transcend Therapeutics's acquisition by Otsuka Pharmaceutical was completed.
EXIT·transcendtherapeutics.com
JUN 2026
Portfolio company Cognition raised $1B+ at a $26B valuation.
MILESTONE·cognition.com
MAY 27, 2026
06Frequent co-investors
IG
ICONIQ Growth
Both backed 5 of the same companies
Anthropic, Uber, Alibaba, OpenAI,
+1 moreMonzo
RC
Ribbit Capital
Both backed 5 of the same companies
Revolut, Cognition, CRED, Policy Bazaar,
+1 moreMonzo
RV
Robinhood Ventures
Both backed 5 of the same companies
Anthropic, Spacex, Revolut, OpenAI,
+1 moreKlarna
SV
SoftBank Vision Fund
Both backed 5 of the same companies
Uber, Revolut, OpenAI, Klarna,
+1 moreSwiggy
2V
2468 Ventures
Both backed 4 of the same companies
Anthropic, Spacex, OpenAI, Cerebras
Find the investors for your round→
07Similar Firms
SV
SoftBank Vision Fund
$100M – $10000M · Series B · Series C
→
SV
Susa Ventures
$500K – $5M · Pre-Seed · Seed
→
G
Greycroft
$2M – $100M · Seed · Series A
→
SC
SquareOne Capital
Seed · Series A
→
IC
Ince Capital
Seed · Series A
→
Quick Reference
Stages
Growth
AUM
$29B
Decision
Investment Committee
Location
New York, NY
Sector Focus
Logistics & Supply ChainCrypto & Web3Mobility & TransportationE-Commerce & MarketplacesFood & BeverageEnterprise SoftwareDeveloper Tools & InfrastructureFintech & PaymentsHealthcare & Digital HealthBiotech & Life SciencesEdTechAerospace & Defense
Models
AI InfrastructureFintechBiotechConsumer
Technology
AI/MLBiotech
See all Logistics & Supply Chain investors →See all Crypto & Web3 investors →See all Mobility & Transportation investors →
Visit alphawaveglobal.com ↗

See how Alpha Wave Global matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Focus Areas
Logistics & Supply ChainCrypto & Web3Mobility & TransportationE-Commerce & MarketplacesFood & BeverageEnterprise SoftwareDeveloper Tools & InfrastructureFintech & PaymentsHealthcare & Digital HealthBiotech & Life SciencesEdTechAerospace & Defense

See how Alpha Wave Global matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Is this your firm? Claim your profile
F4 Intelligence Report · Last Researched September 1, 2026F4 Research Engine